Skip to main content
. 2021 Sep 6;61(1):477–487. doi: 10.1007/s00394-021-02666-1

Fig. 2.

Fig. 2

Quality of life and neurocognition. A Mean aggregated score for global health (Question 29/30) did not show a significant difference between the treatment groups or during the course of the trial. B There was no significant impairment in the activities of daily living estimated by KPS. C, D Each dot represents the individual result of a patient for the d2 test. Red bars indicate the median value. Baseline examination showed a severe impaired sustained attention ability of the patients on the age matched percentile for KD-IF (C) and SD (D). Test results improved significantly for both groups by repetitive testing during the follow-ups